A100G (p.Ala100Gly) variant of KRT16 (Keratin, type I cytoskeletal 16)

A100G (p.Ala100Gly) in KRT16 (Keratin, type I cytoskeletal 16) is a missense change. Clinical records from ClinVar, EBI, and UniProt describe it as likely benign in the context of not provided. The available variant effect predictions contribute to a CATVariant prioritization score of 0.14 / 1. The record also includes population frequency data and structural context.

A100G (p.Ala100Gly) variant details